Home' Australian Pharmacist : Australian Pharmacist January 2015 Contents Australian Pharmacist January 2015 I ©Pharmaceutical Society of Australia Ltd.
1. Which of the following statements is
true regarding stroke risk in patients
a) AF increases the risk of stroke by 5 to 6 fold.
b) The majority of strokes are a direct result
c) Patients with paroxysmal AF are not at
an increased risk of stroke.
d) Stroke is the leading cause of death in
2. Which of the following is an important
counselling point for NOACs?
a) Rivaroxaban 20 mg is best taken on an
b) Apixaban should not be repacked into
dose administration aids.
c) Dabigatran should be taken once daily.
d) Tell your doctor or pharmacist
immediately if you have any unexplained
bruising, bleeding, pink, red or dark
brown urine, or red or black faeces.
3. A physician telephones you to obtain
dosing advice for a patient with
non-valvular AF who he would like
to start on a NOAC. You note the
patient’s creatinine clearance to be
20 mL/min. What treatment would
a) Dabigatran 110 mg twice daily.
b) Rivaroxaban 15 mg daily.
c) Apixaban 2.5 mg twice daily.
d) None of the above. Consider warfarin
4. A 75-year-old female well known to
your pharmacy comes in and tells
you she has a new diagnosis of atrial
fibrillation. Her doctor has suggested
that she needs anticoagulation to
prevent blood clots. The patient has
diabetes and a previous myocardial
infarction. Calculate this patient’s
5. A patient presents to your pharmacy
with a prescription for itraconazole
100 mg daily for four weeks.
The patient states they have been
prescribed this for the management
of a fungal infection on their feet.
You review the patient’s medication
profile and note the patient is on
apixaban 5 mg twice daily. Which of
the following would be the safest
course of action?
a) Dispense itraconazole therapy. No drug
interaction is identified.
b) There is a minor drug interaction which
requires a dose reduction of apixaban to
2.5 mg twice.
c) Drug interaction identified, recommend
changing itraconazole to fluconazole.
d) Drug interaction identified, recommend
changing apixaban to rivaroxaban
20 mg daily.
To submit answers go to: www.psa.org.
click on Australian Pharmacist.
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an
independent risk factor for stroke: the Framingham Study.
2. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the
management of atrial fibrillation: The Task Force for the
management of atrial fibrillation of the European Society
of Cardiology (ESC). Eur Heart J 2010;31(19):2369–429.
3. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and
pathophysiology of atrial fibrillation: Relationships among
clinical features, epidemiology and mechanisms. Circ Res
4. Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation
pathophysiology : implications for management.
Circulation 2011;124(20):2264–74 .
5. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial
fibrillation: mechanisms and implications. Circulation:
Arrhythmia and Electrophysiology. 2008;1(1):62–73.
6. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of
rate control and rhythm control in patients with atrial
fibrillation. New Engl J Med. 2002;347(23):1825–33 .
7. Amerena JV, Walters TE, Mirzaee S, et al. Update on
the management of atrial fibrillation. Med J Aust.
8. Frankel G, Kamrul R, Kosar L, et al. Rate versus rhythm
control in atrial fibrillation. Canadian Family Physician.
9. Department of Health (Western Australia). Quick reference
guide: Atrial Fibrillation Information for the Health
Practitioner 2011. At: www.healthnetworks.health.wa.gov.
10. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused
update of the ESC Guidelines for the management of
atrial fibrillation: An update of the 2010 ESC Guidelines
for the management of atrial fibrillation. Developed with
the special contribution of the European Heart Rhythm
Association. Europace 2012;14(10):1385–413.
11. Keogh C, Wallace E, Dillon C, et al. Validation of the
CHADS2 clinical prediction rule to predict ischaemic
stroke. A systematic review and meta-analysis. Thromb
Haemost 2011;106(9):528–38 .
12. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS
Guideline for the management of patients with atrial
fibrillation: Executive Summary: A report of the American
College of Cardiology/American Heart Association Task
Force on practice guidelines and the Heart Rhythm
Society. Circulation. Epub April 2014.
13. Eikelboom JW, Connolly SJ, Brueckmann M et al.
Dabigatran versus warfarin in patients with mechanical
heart valves. N Engl J Med 2013;369(13):1206–14 .
14. Hart RG, Pearce LA, Aguilar MI. Meta-analysis:
antithrombotic therapy to prevent stroke in patients
who have nonvalvular atrial fibrillation. Ann Intern Med
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran
versus warfarin in patients with atrial fibrillation. N Engl J
16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus
warfarin in nonvalvular atrial fibrillation. N Engl J Med
17. Granger CB, Alexander JH, McMurray JV, et al. Apixaban
versus warfarin in patients with atrial fibrillation. N Engl J
18. Kaatz S. Determinants and measures of quality in
oral anticoagulation therapy. J Thromb Thrombolysis
19. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and
safety of dabigatran compared with warfarin at different
levels of international normalised ratio control for stroke
prevention in atrial fibrillation: an analysis of the RE-LY trial.
20. Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global
geographic region on time in therapeutic range on
warfarin anticoagulant therapy: Data from the ROCKET
AF clinical trial. J Am Heart Assoc 2013;2:e000067 doi:
21. Bereznicki LR, Madden AR, Petersen GM. The quality
of international normalised ratio control in southern
Tasmania. Med J Aust 2013;198(6):315.
22. eMIMs cloud. Sydney: MIMS Australia Pty Ltd; 2014.
23. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran
plasma concentrations and patient characteristics on
the frequency of ischemic stroke and major bleeding in
atrial fibrillation patients: The RE-LY Trial (Randomized
Evaluation of Long-Term Anticoagulation Therapy). J Am
Coll Cardiol 2014;63(4):321–8 .
24. Shah SV, Gage BF. Cost-effectiveness of dabigatran
for stroke prophylaxis in atrial fibrillation. Circulation
25. Ageno W, Crowther M, Baglin T, et al. Selection and
assessment of patients treated with the novel oral
anticoagulant drugs: a recommendation from the
Subcommittee on Control of Anticoagulation of
the Scientific and Standardisation Committee of the
International Society on Thrombosis and Haemostasis. J
Thromb Haemost 2013;11(1):177–9 .
Links Archive Australian Pharmacist December 2014 Australian Pharmacist February 2015 Navigation Previous Page Next Page